Sodium Stibogluconate and Interferon in Treating Patients With Advanced Solid Tumors, Lymphoma, or Myeloma

DISEASE CHARACTERISTICS:

* Histologically confirmed malignancy, including, but not limited to, any of the following:

  * Renal cell carcinoma
  * Melanoma
  * Kaposi's sarcoma
  * Breast, prostate, colorectal, or lung adenocarcinoma
  * Bone and soft tissue sarcomas
  * Lymphoma
  * Myeloma
  * Tumors of neuroendocrine and endothelial cell origin
* Stage IV disease
* Refractory disease, resistant to established treatments, or no effective treatment available
* Measurable or evaluable disease
* CNS metastases allowed if no prior definitive therapy within the past 3 months and no glucocorticoids required

PATIENT CHARACTERISTICS:

* ECOG performance status 0-1
* Granulocyte count \> 1,500/mm\^3
* Platelet count \> 100,000/mm\^3
* Creatinine \< 1.0 times upper limit of normal (ULN)
* Creatinine clearance ≥ 60 mL/min
* Bilirubin \< 1.5 times ULN
* AST/ALT \< 1.5 times ULN
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception during and for 3 months after completion of study treatment
* No history of any of the following:

  * Atrial fibrillation, atrial flutter, or other serious arrhythmia (excluding asymptomatic atrial and ventricular premature complexes)
  * Congestive heart failure currently requiring treatment
  * Angina pectoris
  * Other severe cardiovascular disease (i.e., New York Heart Association class III or IV heart disease)
* No baseline ECG abnormalities suggestive of cardiac conduction delay, i.e., 1° or greater atrio-ventricular block and/or complete or incomplete (QRS \> 120 ms) bundle branch block, or repolarization abnormalities (i.e., QTc ≥ 0.48 sec)
* No systemic infections requiring antibiotics within the past 14 days
* No known hepatitis B surface antigen positivity
* Psychologically prepared to participate in study treatment

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics
* At least 4 weeks since prior interferon (IFN) therapy and/or ≤ 400 million units of IFN
* At least 3 weeks since prior major surgery
* At least 3 weeks since prior radiation therapy or chemotherapy
* No prior solid organ allografts or allogeneic bone marrow transplantation
* No concurrent daily glucocorticoids except for physiological replacement
* No other concurrent medications known to prolong QT interval